Document is current

Any future updates will be listed below

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma

Crossref DOI link: https://doi.org/10.1007/s00277-025-06379-x

Published Online: 2025-04-25

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark